Sildenafil for Treatment of Choroidal Ischemia
Who is this study for? Patients with Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Status: Completed
Location: See location...
Intervention Type: Diagnostic test, Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of retinal and choroidal degenerations (reticular or vitelliform AMD or vitelliform-type subretinal drusen) or hereditary or acquired retinal dystrophies (retinitis pigmentosa or central serous retinopathy)
Locations
United States
New York
Columbia University Medical Center, Edward Harkness Eye Institute
New York
Time Frame
Start Date: 2014-11-11
Completion Date: 2020-02-18
Participants
Target number of participants: 22
Treatments
Active_comparator: Standard of Care Sildenafil
Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
Active_comparator: Sildenafil
Participants are prescribed sildenafil 40-80 mg daily.
Related Therapeutic Areas
Sponsors
Leads: Columbia University